At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 10, 2026 at 08:03 ET
Tyra Biosciences reported Q3 2026 net loss of $51.1M, wider than the $29.9M loss in Q3 2025, driven by increased R&D spending on its dabogratinib clinical programs. The company highlighted initial Phase 2 SURF302 results showing a 79% ORR and 64% CR rate at 60 mg QD in IR NMIBC, and disclosed a $400M September financing that extended cash runway through 2030. No revenue or EPS consensus was provided for the current quarter.
- Q3 2026 net loss of $51.1M vs $29.9M in Q3 2025
- Cash, cash equivalents and marketable securities of $700.5M as of September 30, 2026
- Completed $400M underwritten public offering in September 2026
- Initial Phase 2 SURF302 results: 79% ORR and 64% CR rate at 60 mg QD in IR NMIBC
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access